WO2021037289A3 - 一种重组融合多肽及其应用 - Google Patents

一种重组融合多肽及其应用 Download PDF

Info

Publication number
WO2021037289A3
WO2021037289A3 PCT/CN2020/123551 CN2020123551W WO2021037289A3 WO 2021037289 A3 WO2021037289 A3 WO 2021037289A3 CN 2020123551 W CN2020123551 W CN 2020123551W WO 2021037289 A3 WO2021037289 A3 WO 2021037289A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptide
recombinant fusion
fibrosis
linker1
linker2
Prior art date
Application number
PCT/CN2020/123551
Other languages
English (en)
French (fr)
Other versions
WO2021037289A2 (zh
Inventor
康志安
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to AU2020339061A priority Critical patent/AU2020339061A1/en
Priority to GB2201004.5A priority patent/GB2600845A/en
Priority to CA3149605A priority patent/CA3149605A1/en
Priority to US17/635,952 priority patent/US20220289801A1/en
Publication of WO2021037289A2 publication Critical patent/WO2021037289A2/zh
Publication of WO2021037289A3 publication Critical patent/WO2021037289A3/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种重组融合多肽及其制备方法和其应用。一种重组融合多肽，所述的重组融合多肽由以下通式表述：X-linker1-Y；Y-linker1-X；X-linker2-Y；Y-linker2-X；其中X为：PRCWRGEGGGGIVRRADRAAVPGGGGRGD； Y为：Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL。本发明的重组融合多肽可以治疗各种纤维化疾病及病状，治疗用途包括抗肺纤维化、肝纤维化、皮肤纤维化、肾纤维化和心肌纤维化以及肺部组织病变。
PCT/CN2020/123551 2019-08-27 2020-10-26 一种重组融合多肽及其应用 WO2021037289A2 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020339061A AU2020339061A1 (en) 2019-08-27 2020-10-26 Recombinant fusion polypeptide and use thereof
GB2201004.5A GB2600845A (en) 2019-08-27 2020-10-26 Recombinant fusion polypeptide and use thereof
CA3149605A CA3149605A1 (en) 2019-08-27 2020-10-26 Recombinant fused polypeptide and use thereof
US17/635,952 US20220289801A1 (en) 2019-08-27 2020-10-26 Recombinant fused polypeptide and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910795102.XA CN110511285B (zh) 2019-08-27 2019-08-27 一种重组融合多肽及其应用
CN201910795102.X 2019-08-27

Publications (2)

Publication Number Publication Date
WO2021037289A2 WO2021037289A2 (zh) 2021-03-04
WO2021037289A3 true WO2021037289A3 (zh) 2021-04-22

Family

ID=68627164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/123551 WO2021037289A2 (zh) 2019-08-27 2020-10-26 一种重组融合多肽及其应用

Country Status (6)

Country Link
US (1) US20220289801A1 (zh)
CN (1) CN110511285B (zh)
AU (1) AU2020339061A1 (zh)
CA (1) CA3149605A1 (zh)
GB (1) GB2600845A (zh)
WO (1) WO2021037289A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
CN105713095A (zh) * 2016-03-14 2016-06-29 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
CN110511285A (zh) * 2019-08-27 2019-11-29 南京安吉生物科技有限公司 一种重组融合多肽及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
CN105713095A (zh) * 2016-03-14 2016-06-29 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
CN110511285A (zh) * 2019-08-27 2019-11-29 南京安吉生物科技有限公司 一种重组融合多肽及其应用

Also Published As

Publication number Publication date
GB2600845A (en) 2022-05-11
AU2020339061A1 (en) 2022-03-10
WO2021037289A2 (zh) 2021-03-04
GB202201004D0 (en) 2022-03-09
CA3149605A1 (en) 2021-03-04
US20220289801A1 (en) 2022-09-15
CN110511285B (zh) 2023-01-24
CN110511285A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
WO2021037289A3 (zh) 一种重组融合多肽及其应用
USD865174S1 (en) Shaft assembly for surgical stapler
USD874657S1 (en) Surgical control apparatus
WO2021037290A3 (zh) 一种融合多肽及其应用
JP2015164549A5 (zh)
CA3156303A1 (en) 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES
CA2333567A1 (en) Device to permit offpump beating heart coronary bypass surgery
WO2011156714A3 (en) Systems for preventing formation of blood clots in the left atrium
WO2008154033A4 (en) Cardiac patterning for improving diastolic function
WO2003094856A3 (en) 1l1rl-1 as a cardiovascular disease marker and therapeutic target
WO2008124110A3 (en) Methods for endocardiac ablation
WO2003061455A3 (en) An apical patch and method of use
ZA202201828B (en) Therapeutic fusion proteins
WO2021037292A3 (zh) 一种多肽及其应用
EP3801235A4 (en) PROCEDURE FOR VISUALIZING BODY SURFACE OF A PATIENT AND DETERMINING COORDINATES OF ECG ELECTRODES DURING NON-INVASIVE ELECTROPHYSIOLOGICAL IMAGING OF THE HEART
USD910130S1 (en) Striking face for a golf club head
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
WO2021037291A3 (zh) 具有多功能活性的融合多肽及其应用
WO2003039577A1 (fr) Remedes contre l'oeil sec et des maladies associees a l'oeil sec
Li et al. Giant left atrial appendage aneurysm compressing the left ventricular wall diagnosed by multiple imaging technology
Liang et al. Intraprocedural slow continuous ultrafiltration: A novel strategy to prevent acute hemodynamic decompensation from volume overload during VT ablation.
USD907148S1 (en) Golf club grip
Baburaj et al. Off-pump excision of left atrial appendage aneurysm: a case report
CN207532537U (zh) 手持式扣背装置
CN207100884U (zh) 一种动物外科手术脱毛刷

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20858874

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202201004

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20201026

ENP Entry into the national phase

Ref document number: 3149605

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020339061

Country of ref document: AU

Date of ref document: 20201026

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20858874

Country of ref document: EP

Kind code of ref document: A2